{"pmid":32394513,"title":"Chloroquine and hydroxychloroquine for COVID-19: A word of caution.","text":["Chloroquine and hydroxychloroquine for COVID-19: A word of caution.","Respirology","Annangi, Srinadh","32394513"],"journal":"Respirology","authors":["Annangi, Srinadh"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32394513","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/resp.13845","keywords":["covid-19","chloroquine","hydroxychloroquine","prophylaxis"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666627827858931712,"score":9.490897,"similar":[{"pmid":32496241,"title":"Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?","text":["Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?","Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context.","Indian J Public Health","Nina, Praveen Balabaskaran","Dash, Aditya Prasad","32496241"],"abstract":["Hydroxychloroquine (HCQ), an antimalarial has been proposed as possible treatment for coronavirus disease-2019 (COVID-19). India has approved the use of HCQ for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration has issued Emergency Use Authorization for the use of HCQ to treat COVID-19 in adolescents and adults. In this review, we go over the available evidence for and against HCQ's use as prophylaxis or treatment for COVID-19, especially in the Indian context."],"journal":"Indian J Public Health","authors":["Nina, Praveen Balabaskaran","Dash, Aditya Prasad"],"date":"2020-06-05T11:00:00Z","year":2020,"_id":"32496241","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.4103/ijph.IJPH_496_20","keywords":["covid-19","chloroquine","hydroxychloroquine","prophylaxis"],"locations":["India","Indian"],"countries":["India"],"countries_codes":["IND|India"],"topics":["Treatment"],"weight":1,"_version_":1668712823975313408,"score":94.32021},{"pmid":32348818,"pmcid":"PMC7195137","title":"Risks of Hydroxychloroquine use for COVID-19 prophylaxis.","text":["Risks of Hydroxychloroquine use for COVID-19 prophylaxis.","J Am Acad Dermatol","Sachdeva, Muskaan","Shah, Monica","Ziv, Michael","Leshem, Eyal","Dodiuk-Gad, Roni P","32348818"],"journal":"J Am Acad Dermatol","authors":["Sachdeva, Muskaan","Shah, Monica","Ziv, Michael","Leshem, Eyal","Dodiuk-Gad, Roni P"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32348818","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jaad.2020.04.111","keywords":["covid-19","evidence","hydroxychloroquine","overuse","prophylaxis","risks"],"locations":["Hydroxychloroquine"],"e_drugs":["Hydroxychloroquine"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666138495380357121,"score":75.63078},{"pmid":32457932,"pmcid":"PMC7250427","title":"Chloroquine, hydroxychloroquine and COVID-19.","text":["Chloroquine, hydroxychloroquine and COVID-19.","The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat coronavirus (COVID-19). Political leaders have touted their use and recommended availability to the public. These anti-inflammatory agents have substantial human toxicity with a narrow therapeutic window. CQ and HCQ poisoning cause myocardial depression and profound hypotension due to vasodilation. Bradycardia and ventricular escape rhythms arise from impaired myocardial automaticity and conductivity due to sodium and potassium channel blockade. With cardiotoxicity, ECGs may show widened QRS, atrioventricular heart block and QT interval prolongation. CQ may also cause seizures, often refractory to standard treatment. Of concern is pediatric poisoning, where 1-2 pills of CQ or HCQ can cause serious and potentially fatal toxicity in a toddler. The treatment of CQ/HCQ poisoning includes high-dose intravenous diazepam postulated to have positive ionotropic and antidysrhythmic properties that may antagonize the cardiotoxic effects of CQ. Infusions of epinephrine titrated to treat unstable hypotension, as well as potassium for severe hypokalemia may be required. Current scientific evidence does not support treatment or prophylactic use of these agents for COVID-19 disease. Regulatory and public health authorities recognize that CQ/HCQ may offer little clinical benefit and only add risk requiring further investigation before wider public distribution.","Toxicol Commun","Erickson, T B","Chai, P R","Boyer, E W","32457932"],"abstract":["The media have featured the antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) to treat coronavirus (COVID-19). Political leaders have touted their use and recommended availability to the public. These anti-inflammatory agents have substantial human toxicity with a narrow therapeutic window. CQ and HCQ poisoning cause myocardial depression and profound hypotension due to vasodilation. Bradycardia and ventricular escape rhythms arise from impaired myocardial automaticity and conductivity due to sodium and potassium channel blockade. With cardiotoxicity, ECGs may show widened QRS, atrioventricular heart block and QT interval prolongation. CQ may also cause seizures, often refractory to standard treatment. Of concern is pediatric poisoning, where 1-2 pills of CQ or HCQ can cause serious and potentially fatal toxicity in a toddler. The treatment of CQ/HCQ poisoning includes high-dose intravenous diazepam postulated to have positive ionotropic and antidysrhythmic properties that may antagonize the cardiotoxic effects of CQ. Infusions of epinephrine titrated to treat unstable hypotension, as well as potassium for severe hypokalemia may be required. Current scientific evidence does not support treatment or prophylactic use of these agents for COVID-19 disease. Regulatory and public health authorities recognize that CQ/HCQ may offer little clinical benefit and only add risk requiring further investigation before wider public distribution."],"journal":"Toxicol Commun","authors":["Erickson, T B","Chai, P R","Boyer, E W"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32457932","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/24734306.2020.1757967","keywords":["chloroquine","coronavirus","diazepam","epinephrine","hydroxychloroquine"],"locations":["Bradycardia"],"e_drugs":["Potassium","Hydroxychloroquine","Epinephrine","Chloroquine","Sodium","Diazepam"],"topics":["Treatment"],"weight":1,"_version_":1667967698921848832,"score":75.59887},{"pmid":32373183,"pmcid":"PMC7192209","title":"Chloroquine and hydroxychloroquine in the context of COVID-19.","text":["Chloroquine and hydroxychloroquine in the context of COVID-19.","Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far. This review aims to present the available in vitro and clinical data for the role of chloroquine/hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment.","Drugs Context","Shukla, Ashutosh M","Archibald, Lennox K","Shukla, Aparna Wagle","Mehta, Hiren J","Cherabuddi, Kartikeya","32373183"],"abstract":["Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far. This review aims to present the available in vitro and clinical data for the role of chloroquine/hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment."],"journal":"Drugs Context","authors":["Shukla, Ashutosh M","Archibald, Lennox K","Shukla, Aparna Wagle","Mehta, Hiren J","Cherabuddi, Kartikeya"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32373183","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.7573/dic.2020-4-5","keywords":["covid-19","sars-cov-2","anti-inflammatory","antimalarial","antiviral","chloroquine","hydroxychloroquine","immunomodulatory","pandemic"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1666138496345047040,"score":74.11944},{"pmid":32418732,"title":"Chloroquine and hydroxychloroquine during pregnancy: What do we know?","text":["Chloroquine and hydroxychloroquine during pregnancy: What do we know?","Therapie","Lacroix, Isabelle","Benevent, Justine","Damase-Michel, Christine","32418732"],"journal":"Therapie","authors":["Lacroix, Isabelle","Benevent, Justine","Damase-Michel, Christine"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418732","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.therap.2020.05.004","keywords":["chloroquine","covid-19","hydroxychloroquine","pregnancy"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667159284602896384,"score":74.11944}]}